PRTA Stock — Prothena Corporation plc: Cash, EV, Pipeline

Share price

$8.58

Market cap

$440.5M

Cash

$288.2M

Enterprise value

$152.3M

Balance sheet

Cash	$288.2M
Debt	$0.0M
Net cash	$288.2M
Enterprise value	$152.3M
Basic shares	51.7M shares
Fully diluted shares	63.1M shares
Fully diluted market cap	$541.4M
Cash per share	$5.57

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PRTA daily closes…

Loading price history…

Pipeline assets

Moponetug

Stage not disclosed · Active Modality: antibody

Aliases BMS-986446, PRX005

Target tau

Partnerships Bristol Myers Squibb: U.S. License Agreement (July 30, 2021) and Global License Agreement (July 5, 2023) granting BMS an exclusive license to develop, manufacture, and commercialize antibodies targeting the tau/moponetug collaboration target

Status note Antibody program targeting tau; BMS holds the exclusive U.S. and global licenses. Clinical stage not stated in the excerpts.

PRX019

Stage not disclosed · Active Modality: antibody

Target undisclosed

Partnerships Bristol Myers Squibb: Global License Agreement (May 24, 2024) granting BMS an exclusive license to develop, manufacture, and commercialize products targeting the undisclosed/PRX019 collaboration target

Status note Antibody program against an undisclosed target (PRX019 collaboration target); BMS holds the exclusive global license. Clinical stage not stated in the excerpts.

Coramitug

Stage not disclosed · Active Modality: antibody

Aliases PRX004

Target TTR

Partnerships Novo Nordisk: collaboration; Prothena recognized a development milestone payment from Novo Nordisk in the six months ended June 30, 2026

Indications

ATTR amyloidosis (Stage not disclosed)

Status note Antibody for ATTR amyloidosis partnered with Novo Nordisk; Prothena is eligible for development/commercialization milestones and royalties if Novo Nordisk advances products containing coramitug or derivatives. Clinical stage not stated.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07174310	Phase 3	Recruiting	Collaborator	Hoffmann-La Roche	—	Parkinson's Disease	—
NCT03100149	Phase 2	Active, not recruiting	Collaborator	Hoffmann-La Roche	—	Parkinson's Disease	—
NCT04777331	Phase 2	Active, not recruiting	Collaborator	Hoffmann-La Roche	—	Parkinsons Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Hoffmann-La Roche on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	1,554,535	-26,908	0.72%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

PRTA — Prothena Corporation plc

Balance sheet

Price history

Pipeline assets

Active clinical trials

Institutional holders